Oropharyngeal Candidiasis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for oropharyngeal candidiasis. 7 active patents protecting 2 drugs from 2+ originators. First major cliff: 2042. Daily refresh.

2
Approved drugs
7
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Oropharyngeal Candidiasis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sebela Ireland Ltd 6 patents Bayer AG 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating oropharyngeal candidiasis. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
28
5
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sporanox
itraconazole
 Sebela Ireland Ltd 6 55 — 2028-10-03
Lotrimin
clotrimazole
 Bayer AG 1 75 — 2042-05-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8486456 Sporanox method of use 80 2028-10-03
12246006 Lotrimin method of use 75 2042-05-26
10463740 Sporanox method of use 62 2033-06-21
9713642 Sporanox method of use 62 2033-06-21
9272046 Sporanox formulation 42 2033-06-21
8921374 Sporanox formulation 42 2033-06-21
10806792 Sporanox formulation 42 2033-06-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10806792 Sporanox formulation 42 2033-06-21
9272046 Sporanox formulation 42 2033-06-21
8921374 Sporanox formulation 42 2033-06-21
10463740 Sporanox method of use 62 2033-06-21
9713642 Sporanox method of use 62 2033-06-21
12246006 Lotrimin method of use 75 2042-05-26
8486456 Sporanox method of use 80 2028-10-03

Related